Cancer therapy with a parvovirus combined with bevacizumab

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10813959
APP PUB NO 20180028583A1
SERIAL NO

15550354

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
DEUTSCHES KREBSFORSCHUNGSZENTRUMIM NEUENHEIMER FELD 280 69120 HEIDELBERG GERMANY
RUPRECHT-KARLS-UNIVERSITAT69117 HEIDELBERG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dahm, Michael Munich, DE 8 44
Geletneky, Karsten Heidelberg, DE 15 44
Rommelaere, Jean Heidelberg, DE 48 78
Wick, Antje Heidelberg, DE 2 0
Wick, Wolfgang Heidelberg, DE 31 127

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 27, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 27, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00